Expand all sections

Masitinib

Masipro

Extended indication Multiple sclerosis, primary-progressive or relapse-free secondary progressive
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Masitinib
Domain Neurological disorders
Main indication Multiple sclerosis
Extended indication Multiple sclerosis, primary-progressive or relapse-free secondary progressive
Proprietary name Masipro
Manufacturer AB Science
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks Al als diergeneesmiddel op de markt sinds 2009 voor behandeling van mast-cel tumoren (Masivet).

Registration

Registration route Centralised (EMA)
Particularity New medicine
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.